PB 117 of 2026

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (October Update) Instrument 2026

National Health Act 1953

I, MIKE POPE, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 30 September 2026

MIKE POPE
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Contents

1. Name....1
2. Commencement....1
3. Authority....1
4. Schedules....1

Schedule 1—Amendments....2

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)....2

Authorised Version F2026L01338 registered 30/09/2026

1. Name

(1) This instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (October Update) Instrument 2026*.

(2) This instrument may also be cited as PB 117 of 2026.

2. Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information

Column 1	Column 2	Column 3
Provisions	**Commencement**	**Date/Details**
1. The whole of this instrument	1 October 2026	1 October 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3. Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

4. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Authorised Version F2026L01338 registered 30/09/2026

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)

[1] Schedule 1, Part 1, entry for Bleomycin

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

	Bleomycin Accord	C6224 C6275

[2] Schedule 1, Part 1, after entry for Paclitaxel, nanoparticle albumin-bound *[Brand: Abraxane]*

insert:

	nab-Paclitaxel Accord	C4657 C6106 C6119

[3] Schedule 1, Part 1, entry for Pembrolizumab

(a) omit from the column headed "Circumstances": C18371

(b) omit from the column headed "Circumstances": C18450

[4] Schedule 1, Part 2, entry for Pembrolizumab *[Maximum Amount: 400 mg; Number of Repeats: 7]*

(a) omit from the column headed "Purposes": P18371

(b) omit from the column headed "Purposes": P18450

[5] Schedule 3, Part 1, omit entry for Circumstances Code "C18371"

[6] Schedule 3, Part 1, omit entry for Circumstances Code "C18450"

Authorised Version F2026L01338 registered 30/09/2026